TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation

European Heart Journal

25 August 2023
Organised by: Logo
ESC Journals Cardiovascular Surgery Interventional Cardiology VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Valvular Heart Disease

Abstract

AbstractBackground and aims

Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to a TR clinical stage as assessed using the TRI-SCORE.

Methods

A total of 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery, and 645 transcatheter valve repair). The primary endpoint was survival at 2 years.

Results

The TRI-SCORE was low (≤3) in 32%, intermediate (4–5) in 33%, and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P < .0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87%, and 79%, respectively, P = .0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71%, and 71%, respectively, P = .13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81%, and 71%, respectively, P = .009). In the high TRI-SCORE category, survival was not different to conservative management in the surgical and successful repair group (61% and 68% vs 58%, P = .26 and P = .18 respectively).

Conclusions

Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.

Contributors

Xavier Galloo
Xavier Galloo

Author

University Hospital (UZ) Brussels Brussels , Belgium

Gregor Heitzinger
Gregor Heitzinger

Author

Medical University of Vienna Vienna , Austria

Hazem Omran
Hazem Omran

Author

Heart and Diabetes Center NRW Bad Oeynhausen , Germany

Fabien Praz
Fabien Praz

Author

University of Bern Bern , Switzerland

Vincent Chan
Vincent Chan

Author

Ottawa Heart Institute Ottawa , Canada

Roman Pfister
Roman Pfister

Author

Cologne University Hospital - Heart Center Cologne , Germany

David Messika-Zeitoun
David Messika-Zeitoun

Author

University of Ottawa Heart Institute Ottawa , Canada

Neil Fam
Neil Fam

Author